[go: up one dir, main page]

DK3004388T3 - Påvisning og kvantificering af cellefrit dna fra donor i kredsløbet hos organtransplantatmodtagere - Google Patents

Påvisning og kvantificering af cellefrit dna fra donor i kredsløbet hos organtransplantatmodtagere Download PDF

Info

Publication number
DK3004388T3
DK3004388T3 DK14804474.6T DK14804474T DK3004388T3 DK 3004388 T3 DK3004388 T3 DK 3004388T3 DK 14804474 T DK14804474 T DK 14804474T DK 3004388 T3 DK3004388 T3 DK 3004388T3
Authority
DK
Denmark
Prior art keywords
donor
snp
graft
cfdna
recipient
Prior art date
Application number
DK14804474.6T
Other languages
English (en)
Other versions
DK3004388T4 (da
Inventor
Ekkehard Schutz
Julia Beck
Original Assignee
Chronix Biomedical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51989530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3004388(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chronix Biomedical filed Critical Chronix Biomedical
Application granted granted Critical
Publication of DK3004388T3 publication Critical patent/DK3004388T3/da
Publication of DK3004388T4 publication Critical patent/DK3004388T4/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Transplanting Machines (AREA)

Claims (13)

1. Fremgangsmåde til evaluering af integriteten af et transplantat hos en modtager, hvilken fremgangsmåde omfatter monitorering af niveauet af graft-cellefrit DNA (cfDNA) ved vurdering af mængden af en donor-SNP-allel i en cfDNA-prøve opnået fra blod fra en patient, hvor SNP-allellen er forhåndsvalgt som havende en mindre allelfrekvens (MAF) på mindst 0,4, og endvidere hvor donor-SNP-allellen er til stede hos donoren og modtageren er homozygotisk for en alternativ allel for denne SNP, hvor SNP-allellen identificeres uden anvendelse af en separat prøve fra en donor.
2. Fremgangsmåde ifølge krav 1, hvor kvantificering af niveauet af donor-SNP-allellen i cfDNA-prøven omfatter bestemmelse af kopiantal af donor-SNP-allellen i cfDNA-prøven eller bestemmelse af procentsatsen af donor-SNP-allellen i cfDNA-prøven.
3. Fremgangsmåde ifølge krav 1 eller 2, hvor (i) det transplanterede materiale er et marginalt organ; (ii) cfDNA-prøven er fra en blodprøve opnået ti dage eller længere efter transplantation; et år eller længere efter transplantation; eller inden for syv dage efter transplantation; (iii) donorvævet er en lever, et hjerte eller en nyre; og/eller (iv) fremgangsmåden endvidere omfatter påvisning af donorspecifikke antistoffer i modtagerens blod.
4. Fremgangsmåde til påvisning af en SNP fra en donor for at monitorere transplantatintegritet hos en modtager, der modtager væv fra donoren, hvilken fremgangsmåde omfatter: (a) identificering af, at en SNP med en mindre allelfrekvens på 0,4 eller højere er homozygotisk hos modtageren; (b) amplificering af cellefrit (cfDNA) fra en serum- eller plasmaprøve opnået fra modtageren mindst 5 dage efter transplantation af materialet fra donoren; (c) udførelse af en kvantitativ PCR-reaktion for de SNP’er, der er identificeret i (a), fir at påvise tilstedeværelsen af den alternative allel for én eller flere af SNP’erne; og (d) udvælgelse af en SNP, hvor den alternative SNP er til stede i det amplificerede cfDNA for at monitorere patientens transplantatintegritet.
5. Fremgangsmåde ifølge krav 4, hvor (i) trin (a) udføres ved anvendelse af DNA isoleret fra perifere blodleukocytter opnået fra patienten eller ved anvendelse af cfDNA’et fra trin (b); (ii) SNP’en med en mindre allelfrekvens på 0,4 eller højere er en SNP ifølge tabel 1; og/eller (iii) SNP’en valgt i (d) er homozygotisk hos donoren.
6. Fremgangsmåde til påvisning af en SNP fra en donor for at monitorere transplantatintegritet hos en modtager, der modtager væv fra donoren, hvilken fremgangsmåde omfatter: (a) identificering af, at en SNP med en mindre allelfrekvens på 0,4 eller højere er homozygotisk hos modtageren; (b) amplificering af cellefrit (cfDNA) fra en blodprøve opnået fra modtageren 24 timer eller mindre efter transplantation af et graftmateriale fra donoren; (c) identificering af en SNP med en mindre allelfrekvens på 0,4 eller højere som homozygotisk hos donoren ved anvendelse af cfDNA’et fra trin (b); (d) udførelse af en kvantitativ PCR-reaktion for de SNP’er, der er identificeret i (a), for at påvise tilstedeværelsen af den alternative allel for én eller flere af SNP’erne hos donoren, og (e) udvælgelse af en SNP, hvor den alternative SNP er homozygotisk hos donoren.
7. Fremgangsmåde ifølge krav 6, hvor (i) trin (a) udføres ved anvendelse af DNA isoleret fra perifere blodleukocytter opnået fra patienten; og/eller (ii) SNP’en med en mindre allelfrekvens på 0,4 eller højere er en SNP ifølge tabel 1.
8. Fremgangsmåde ifølge et hvilket som helst af kravene 4 til 7, der endvidere omfatter opnåelse af en cfDNA-prøve fra modtageren efter transplantation af donorvæv; and kvantificering af niveauet af donor-SNP-allellen i cfDNA-prøven, eventuelt hvor (i) kvantificeringstrinnet omfatter bestemmelse af kopiantal af donor-SNP-allellen i cfDNA-prøven eller bestemmelse af procentsatsen af donor-SNP-allellen i cfDNA-prøven; (ii) det transplanterede materiale er et marginalt organ; (iii) cfDNA-prøven er fra en blodprøve opnået ti dage eller længere efter transplantation; eller et år eller længere efter transplantation; eventuelt hvor fremgangsmåden endvidere omfatter justering af en administrationsplan eller dosering eller af et immunsuppressivt lægemiddel; (iv) cfDNA-prøven er fra en blodprøve opnået inden for syv dage efter transplantation; (v) donorvævet er en lever, et hjerte eller en nyre; og/eller (vi) fremgangsmåden endvidere omfatter påvisning af donorspecifikke antistoffer i modtagerens blod.
9. Anvendelse af fremgangsmåden ifølge kravene 1 til 3 eller 8 til: påvisning af reperfusionsskade på donorvæv hos en transplantatmodtager; påvisning af skade på donorlevervæv forårsaget af en hepatitis virus hos en transplantatmodtager, påvisning af kronisk graftnefropati eller påvisning af graftvaskulopati; bestemmelse af den minimale virksomme dosis af et immunsuppressivt lægemiddel; og/eller påvisning af transplantatskade fra donorspecifikke antistoffer eller en kronisk transplantatslæsion.
10. Fremgangsmåde til monitorering af integriteten af et transplantat hos en transplantatmodtager, hvilken fremgangsmåde omfatter kvantificering, i en cfDNA-prøve opnået fra transplantatmodtageren af mængden af en donor-SNP-allel til en SNP valgt i et hvilket som helst af kravene 1 til 6.
11. Fremgangsmåde ifølge krav 10, hvor (i) transplantatet er et marginalt organ; (ii) transplantatet monitoreres for at påvise reperfusionsskade; (iii) transplantatet monitoreres for at bestemme den laveste virksomme dosis af et immunsuppressivt lægemiddel; (iv) transplantatet monitoreres for at påvise skade på transplantatet fra donorspecifikke antistoffer eller (v) transplantatet er en lever, nyre eller et hjerte.
12. Fremgangsmåde ifølge et hvilket som helst af kravene 1 til 3, hvor SNP’en vælges ved anvendelse afen fremgangsmåde ifølge et hvilket som helst af kravene 4 til 8.
13. Fremgangsmåde ifølge et hvilket som helst af kravene 4 til 7, hvor den kvantitative PCR er realtids-PCR.
DK14804474.6T 2013-05-29 2014-05-29 Påvisning og kvantificering af cellefrit dna fra donor i kredsløbet hos organtransplantatmodtagere DK3004388T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361828553P 2013-05-29 2013-05-29
PCT/US2014/040055 WO2014194113A2 (en) 2013-05-29 2014-05-29 Detection and quantification of donor cell-free dna in the circulation of organ transplant recipients

Publications (2)

Publication Number Publication Date
DK3004388T3 true DK3004388T3 (da) 2019-02-04
DK3004388T4 DK3004388T4 (da) 2023-08-28

Family

ID=51989530

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14804474.6T DK3004388T4 (da) 2013-05-29 2014-05-29 Påvisning og kvantificering af cellefrit dna fra donor i kredsløbet hos organtransplantatmodtagere

Country Status (12)

Country Link
US (3) US20160115541A1 (da)
EP (1) EP3004388B2 (da)
CY (1) CY1122332T1 (da)
DK (1) DK3004388T4 (da)
ES (1) ES2704682T5 (da)
HR (1) HRP20190209T4 (da)
HU (1) HUE041935T2 (da)
LT (1) LT3004388T (da)
PL (1) PL3004388T5 (da)
PT (1) PT3004388T (da)
SI (1) SI3004388T2 (da)
WO (1) WO2014194113A2 (da)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
AU2011255641A1 (en) 2010-05-18 2012-12-06 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US9677118B2 (en) 2014-04-21 2017-06-13 Natera, Inc. Methods for simultaneous amplification of target loci
EP2673729B1 (en) 2011-02-09 2018-10-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
CA2870969C (en) 2012-04-19 2023-10-03 Aoy Tomita Mitchell Highly sensitive surveillance using detection of cell free dna
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
HUE043288T2 (hu) 2014-03-14 2019-08-28 Caredx Inc Eljárások immunszuppresszív terápiák monitorozására transzplantátum recipiensben
CN113774132A (zh) 2014-04-21 2021-12-10 纳特拉公司 检测染色体片段中的突变和倍性
US20180173845A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
US10435750B2 (en) * 2014-07-03 2019-10-08 Multiplicom N.V. Methods for non-invasive detection of transplant health or rejection
JP2017522908A (ja) 2014-07-25 2017-08-17 ユニヴァーシティ オブ ワシントン セルフリーｄｎａを生じる組織及び／又は細胞タイプを決定する方法、並びにそれを用いて疾患又は異常を識別する方法
WO2016123698A1 (en) * 2015-02-06 2016-08-11 Uti Limited Partnership Diagnostic assay for post-transplant assessment of potential rejection of donor organs
KR101850437B1 (ko) * 2015-04-14 2018-04-20 이원다이애그노믹스(주) 차세대 염기서열 분석기법을 이용한 장기 이식 거부 반응 예측 방법
BR112017023232A2 (pt) * 2015-04-30 2018-08-07 Medical College Of Wisconsin Inc pcr em tempo real da amplificação da ligação imperfeita diversificada otimizada (moma) para a avaliação do dna livre de células
DK3294906T3 (en) 2015-05-11 2024-08-05 Natera Inc Methods for determining ploidy
CN106544407B (zh) * 2015-09-18 2019-11-08 广州华大基因医学检验所有限公司 确定受体cfDNA样本中供体来源cfDNA比例的方法
ES2913468T3 (es) 2016-04-15 2022-06-02 Natera Inc Métodos para la detección del cáncer de pulmón.
EP3449019B1 (en) * 2016-04-29 2023-08-23 The Medical College of Wisconsin, Inc. Multiplexed optimized mismatch amplification (moma)-target number
US11485996B2 (en) 2016-10-04 2022-11-01 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
AU2017355458A1 (en) * 2016-11-02 2019-06-13 The Medical College Of Wisconsin, Inc. Methods for assessing risk using mismatch amplification and statistical methods
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
US20190367972A1 (en) * 2016-11-02 2019-12-05 The Medical College Of Wisconsin, Inc. Methods for assessing risk using total and specific cell-free dna
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
FR3061720B1 (fr) * 2017-01-06 2021-04-16 Cfid Solutions Procede de detection et quantification d'adn circulant et utilisations
WO2018237075A1 (en) 2017-06-20 2018-12-27 The Medical College Of Wisconsin, Inc. Assessing transplant complication risk with total cell-free dna
AU2018288838A1 (en) * 2017-06-20 2020-01-16 The Medical College Of Wisconsin, Inc. Transplant patient monitoring with cell-free DNA
AU2018301716B2 (en) 2017-07-14 2024-06-13 The Regents Of The University Of California Novel methods of predicting transplant rejection risk
US12084720B2 (en) 2017-12-14 2024-09-10 Natera, Inc. Assessing graft suitability for transplantation
SG11202005474RA (en) 2017-12-15 2020-07-29 Acrannolife Genomics Pvt Ltd A non-invasive method for monitoring transplanted organ status in organ-transplant recipients
EP3517629A1 (en) 2018-01-30 2019-07-31 Myway Genetics S.r.L. Use of cfdna fragments as biomarkers in patients after organ transplantation
WO2019200228A1 (en) 2018-04-14 2019-10-17 Natera, Inc. Methods for cancer detection and monitoring by means of personalized detection of circulating tumor dna
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
WO2020076957A1 (en) * 2018-10-09 2020-04-16 Tai Diagnostics, Inc. Cell lysis assay for cell-free dna analysis
US20220073989A1 (en) * 2018-12-20 2022-03-10 The Regents Of The University Of California Optimizing Detection of Transplant Injury by Donor-Derived Cell-Free DNA
JP2022526984A (ja) * 2019-04-03 2022-05-27 ザ メディカル カレッジ オブ ウィスコンシン，インコーポレイテッド 無細胞ｄｎａでの移植患者の監視
US11931674B2 (en) 2019-04-04 2024-03-19 Natera, Inc. Materials and methods for processing blood samples
WO2020247263A1 (en) 2019-06-06 2020-12-10 Natera, Inc. Methods for detecting immune cell dna and monitoring immune system
CN114645077B (zh) * 2020-12-17 2025-06-03 厦门大学 一种检测受体样品中供体的存在或比例的方法和试剂盒
CN113061666A (zh) * 2020-12-30 2021-07-02 中南大学湘雅二医院 肝移植后巨细胞病毒的检测方法、应用及系统
WO2023116717A1 (en) * 2021-12-22 2023-06-29 The First Affiliated Hospital Of Guangzhou Medical University Method for monitoring donar dna fraction
CN114381511A (zh) * 2021-12-31 2022-04-22 上海药明奥测医疗科技有限公司 一种评估肝移植术后移植物损伤及排斥风险的检测方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI891436L (fi) 1987-07-31 1989-03-23 Univ Leland Stanford Junior Selektivt flerfaldigande av targetpolynukleotidsekvenser.
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
CA2020958C (en) 1989-07-11 2005-01-11 Daniel L. Kacian Nucleic acid sequence amplification methods
US5955589A (en) 1991-12-24 1999-09-21 Isis Pharmaceuticals Inc. Gapped 2' modified oligonucleotides
IL100040A (en) 1990-11-13 1995-12-31 Siska Diagnostics Inc Nucleic acid amplification by two enzyme self-sustained sequence replication
YU187991A (sh) 1990-12-11 1994-09-09 Hoechst Aktiengesellschaft 3-(2)-amino-ali tiol-modifikovani, s fluorescentnom bojom vezani nukleozidi, nukleotidi i oligonukleotidi, postupak za njihovo dobijanje i njihova upotreba
US5455166A (en) 1991-01-31 1995-10-03 Becton, Dickinson And Company Strand displacement amplification
US5652099A (en) 1992-02-12 1997-07-29 Conrad; Michael J. Probes comprising fluorescent nucleosides and uses thereof
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
DE4415370A1 (de) 1994-05-02 1995-11-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
DE4438918A1 (de) 1994-11-04 1996-05-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
DE69827060T2 (de) 1997-03-20 2005-03-24 F. Hoffmann-La Roche Ag Modifizierte Primer
US6440706B1 (en) 1999-08-02 2002-08-27 Johns Hopkins University Digital amplification
ES2274861T3 (es) * 2001-12-24 2007-06-01 Wolfgang Prof. Holzgreve Metodo para el diagnostico no-invasivo de transplantes y transfusiones.
CA2677517C (en) † 2007-02-08 2015-11-03 Sequenom, Inc. Nucleic acid-based tests for rhd typing, gender determination and nucleic acid quantification
AU2008230813B2 (en) * 2007-03-26 2014-01-30 Sequenom, Inc. Restriction endonuclease enhanced polymorphic sequence detection
CA2700831A1 (en) * 2007-09-28 2009-04-09 Stryker Corporation Methods for detecting neutralizing antibodies for bone morphogenetic proteins
US20120034603A1 (en) * 2010-08-06 2012-02-09 Tandem Diagnostics, Inc. Ligation-based detection of genetic variants
US10072294B2 (en) † 2011-02-22 2018-09-11 City Of Hope Ultra-high sensitive monitoring of early transplantation failure
CA2870969C (en) † 2012-04-19 2023-10-03 Aoy Tomita Mitchell Highly sensitive surveillance using detection of cell free dna
HUE043288T2 (hu) * 2014-03-14 2019-08-28 Caredx Inc Eljárások immunszuppresszív terápiák monitorozására transzplantátum recipiensben

Also Published As

Publication number Publication date
US20220025459A1 (en) 2022-01-27
EP3004388B2 (en) 2023-05-31
SI3004388T2 (sl) 2023-11-30
ES2704682T5 (es) 2023-11-10
EP3004388B1 (en) 2018-10-31
WO2014194113A3 (en) 2015-01-22
DK3004388T4 (da) 2023-08-28
EP3004388A2 (en) 2016-04-13
WO2014194113A2 (en) 2014-12-04
EP3004388A4 (en) 2017-01-11
US20180346982A1 (en) 2018-12-06
HUE041935T2 (hu) 2019-06-28
HRP20190209T4 (hr) 2023-09-15
CY1122332T1 (el) 2021-01-27
HRP20190209T1 (hr) 2019-04-05
US11155872B2 (en) 2021-10-26
SI3004388T1 (sl) 2019-03-29
PT3004388T (pt) 2019-01-29
LT3004388T (lt) 2019-01-25
US20160115541A1 (en) 2016-04-28
ES2704682T3 (es) 2019-03-19
PL3004388T5 (pl) 2023-10-09
PL3004388T3 (pl) 2019-04-30

Similar Documents

Publication Publication Date Title
DK3004388T3 (da) Påvisning og kvantificering af cellefrit dna fra donor i kredsløbet hos organtransplantatmodtagere
AU2022279551B2 (en) Non-invasive diagnosis of graft rejection in organ transplant patients
US20230087365A1 (en) Prostate cancer associated circulating nucleic acid biomarkers
US20220333213A1 (en) Breast cancer associated circulating nucleic acid biomarkers
US20230203573A1 (en) Methods for detection of donor-derived cell-free dna
US10570443B2 (en) Methods of quantifying cell-free DNA
US20110183856A1 (en) Diagnosis and Prognosis of Infectious Disease Clinical Phenotypes and other Physiologic States Using Host Gene Expression Biomarkers In Blood
WO2018237078A1 (en) Assessing conditions in transplant subjects using donor-specific cell-free dna
Brym et al. Evaluation of reference genes for qRT-PCR gene expression studies in whole blood samples from healthy and leukemia-virus infected cattle
US7883851B2 (en) Common allele on chromosome 9 associated with coronary heart disease
WO2014181107A1 (en) Genetic method of aiding the diagnosis and treatment of familial hypercholersterolaemia
KR101536213B1 (ko) 복부비만 예측용 ｓｎｐ 마커 및 이의 용도
KR101532308B1 (ko) 복부비만 예측용 ｓｎｐ 마커 및 이의 용도
KR102741661B1 (ko) 레티놀을 포함하는 처방의 자극 유무 예측 방법 및 시스템
KR102156699B1 (ko) 소음인 판별용 조성물
US20040043405A1 (en) Nucleic acid detection assay control genes
US20160051527A1 (en) Methods and kits for treating and classifying individuals at risk of or suffering from a neurological dysfunction or disorder
US20120190656A1 (en) Methods for selecting therapies to improve hdl cholesterol and triglyceride levels
CHOONG et al. Development of an algorithm of satellite markers for monitoring chimerism status in post‐allogeneic haematopoietic stem cell transplantation patients
CN119301684A (zh) 用于鉴定基因变体的方法和系统
HK40037908A (en) Non-invasive diagnosis of graft rejection in organ transplant patients
AU2014304302A1 (en) Predictive method for bone fracture risk in horses and humans